Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Bullish +75

Why TIME ranked Moderna the world's most impactful company in 2026 - Stock Titan

🏆 Moderna ranked #1 on TIME's 2026 World's Most Impactful Companies list based on the Upright Project's Net Impact Model.

💉 European regulatory approval granted in 2026 for mCOMBRIAX, a flu plus COVID combination vaccine.

🤝 Strategic partnerships expanded with the UK, Canada, and Australia to boost pandemic preparedness and manufacturing capacity.

🔬 mRNA Access program now includes 35 institutions globally researching vaccines for emerging infectious diseases.

📅 Moderna celebrated the fourth anniversary of its Charitable Foundation and released its fourth annual Impacting Human Health Report.

🧬 CEO Stéphane Bancel emphasized the team's dedication to advancing mRNA science for patients and communities worldwide.

Bullish Signals
  • Moderna secured the top spot on TIME's prestigious 2026 list, validating its leadership in mRNA technology and societal impact.
  • The European approval of mCOMBRIAX expands Moderna's product portfolio with a novel single-shot combination vaccine for flu and COVID.
  • Strategic alliances with major nations like the UK, Canada, and Australia demonstrate strong government confidence in Moderna's pandemic readiness capabilities.
  • The growth of the mRNA Access program to 35 institutions showcases the company's success in fostering open scientific collaboration for neglected diseases.
Full Analysis
Moderna (NASDAQ:MRNA) was ranked number one on TIME's 2026 list of the World's Most Impactful Companies, a distinction based on the Upright Project's Net Impact Model which evaluates net-positive contributions across Society, Knowledge, Health, and Environment. The recognition highlights Moderna's status as a pioneer in mRNA technology and its commitment to delivering meaningful benefits for patients and society through innovative medicines addressing unmet needs in infectious diseases, oncology, and rare diseases. In 2026, the company achieved a significant regulatory milestone with European approval for mCOMBRIAX, its fourth product and first combination vaccine targeting both flu and COVID. This expansion of its respiratory portfolio supports broader pandemic preparedness efforts. Additionally, Moderna deepened long-term strategic partnerships with the UK, Canada, and Australia to expand manufacturing capacity and minimize response times for future pandemics. Beyond commercial products, Moderna highlighted its commitment to global health equity through its mRNA Access program, which has grown to include 35 institutions worldwide since its 2022 launch. The company also marked the fourth anniversary of its Charitable Foundation and published its fourth annual Impacting Human Health Report, reinforcing its focus on societal impact alongside scientific advancement.